Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D

Psychological Medicine

Volumn 42, Issue 6, 2012, Pages 1151-1162

  Clark, S L ^a   Adkins, D E ^a   Aberg, K ^a   Hettema, J M ^a   McClay, J L ^a   Souza, R P ^b   Van Den Oord, E J C G ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

Author keywords

Depression; Genome wide association study; Pharmacogenomics; Side effects; Single nucleotide polymorphisms; STAR*D

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; MEMBRANE PROTEIN; SACM1L PROTEIN, HUMAN;

ARTICLE; CHEMICALLY INDUCED DISORDER; CLASSIFICATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOXICITY; FACTORIAL ANALYSIS; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; HUMAN; MAJOR DEPRESSION; PHARMACOGENETICS; PHENOTYPE; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL MODEL; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; BUPROPION; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DRUG TOXICITY; FACTOR ANALYSIS, STATISTICAL; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LINEAR MODELS; LINKAGE DISEQUILIBRIUM; MEMBRANE PROTEINS; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TREATMENT OUTCOME;

EID: 84860760398     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S003329171100239X     Document Type: Article

References (71)

1. Aberg K, Adkins DE, Bukszar J, Webb BT, Caroff SN, Miller DD, Sebat J, Stroup S, Fanous AH, Vladimirov VI, McClay JL, Lieberman JA, Sullivan PF, van den Oord EJ (2010a). Genomewide association study of movementrelated adverse antipsychotic effects. Biological Psychiatry 67, 279-282.
2. Aberg K, Adkins DE, Liu Y, McClay JL, Bukszar J, Jia P, Zhao Z, Perkins D, Stroup TS, Lieberman JA, Sullivan PF, van den Oord EJ (2010b). Genome-wide association study of antipsychotic-induced QTc interval prolongation. Pharmacogenomics Journal. Published online: 5 October 2010. doi:10.1038/tpj. 2010.76.
3. Adkins DE, Aberg K, McClay JL, Bukszar J, Zhao Z, Jia P, Stroup TS, Perkins D, McEvoy JP, Lieberman JA, Sullivan PF, van den Oord EJ (2011). Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. Molecular Psychiatry 16, 321-332.
4. Adkins DE, Aberg K, McClay JL, Hettema JM, Kornstein SG, Bukszar J, van den Oord EJ (2010). A genomewide association study of citalopram response in major depressive disorder-a psychometric approach. Biological Psychiatry 68, e25-e27.
5. Altshuler D, Daly MJ, Lander ES (2008). Genetic mapping in human disease. Science 322, 881-888.
6. Ayala ME (2009). Brain serotonin, psychoactive drugs, and effects on reproduction. Central Nervous System Agents in Medicinal Chemistry 9, 258-276.
7. Barbee JG (1998). Mixed symptoms and syndromes of anxiety and depression: diagnostic, prognostic, and etiologic issues. Annals of Clinical Psychiatry 10, 15-29%. (Pubitemid 28258682)
8. Barrett JC, Fry B, Maller J, Daly MJ (2005). Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21, 263-265. (Pubitemid 40202029)
9. Beecham GW, Martin ER, Li YJ, Slifer MA, Gilbert JR, Haines JL, Pericak-Vance MA (2009). Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. American Journal of Human Genetics 84, 35-43.
10. Benjamini Y, Hochberg Y (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society. Series B (Methodological) 57, 289-300.
11. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C, Onofrio R, Carter SL, Park K, Habegger L, Ambrogio L, Fennell T, Parkin M, Saksena G, Voet D, Ramos AH, Pugh TJ, Wilkinson J, Fisher S, Winckler W, Mahan S, Ardlie K, Baldwin J, Simons JW, Kitabayashi N, Macdonald TY, Kantoff PW, Chin L, Gabriel SB, Gerstein MB, Golub TR, Meyerson M, Tewari A, Lander ES, Getz G, Rubin MA, Garraway LA (2011). The genomic complexity of primary human prostate cancer. Nature 470, 214-220.
12. Black MA (2004). A note on the adaptive control of false discovery rates. Journal of the Royal Statistical Society. Series B 66, 297-304%. (Pubitemid 38652721)
13. Blagoveshchenskaya A, Cheong FY, Rohde HM, Glover G, Knodler A, Nicolson T, Boehmelt G, Mayinger P (2008). Integration of Golgi trafficking and growth factor signaling by the lipid phosphatase SAC1. Journal of Cell Biology 180, 803-812. (Pubitemid 351397779)
14. Bollen KA (1989). Structural Equations with Latent Variables. Wiley: New York.
15. Brown BW, Russell K (1997). Methods correcting for multiple testing: operating characteristics. Statistics in Medicine 16, 2511-2528. (Pubitemid 27490058)
16. Bull SA, Hu XH, Hunkeler EM, Lee JY, Ming EE, Markson LE, Fireman B (2002a). Discontinuation of use and switching of antidepressants: influence of patient-physician communication. Journal of the American Medical Association 288, 1403-1409. (Pubitemid 35025915)
17. Bull SA, Hunkeler EM, Lee JY, Rowland CR, Williamson TE, Schwab JR, Hurt SW (2002b). Discontinuing or switching selective serotonin-reuptake inhibitors. Annals of Pharmacotherapy 36, 578-584. (Pubitemid 34270268)
18. Byun E, Caillier SJ, Montalban X, Villoslada P, Fernandez O, Brassat D, Comabella M, Wang J, Barcellos LF, Baranzini SE, Oksenberg JR (2008). Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Archives of Neurology 65, 337-344. (Pubitemid 351398518)
19. Chen QY, Chen Q, Feng GY, Lindpaintner K, Chen Y, Sun X, Chen Z, Gao Z, Tang J, He L (2005). Case-control association study of the close homologue of L1 (CHL1) gene and schizophrenia in the Chinese population. Schizophrenia Research 73, 269-274. (Pubitemid 40093889)
20. Clayton AH, Warnock JK, Kornstein SG, Pinkerton R, Sheldon-Keller A, McGarvey EL (2004). A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. Journal of Clinical Psychiatry 65, 62-67.
21. Corona G, Maggi M (2010). The role of testosterone in erectile dysfunction. Nature Reviews. Urology 7, 46-56.
22. Demyttenaere K, Albert A, Mesters P, Dewe W, De Bruyckere K, Sangeleer M (2005). What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors ? Journal of Clinical Psychiatry 66, 859-863. (Pubitemid 41032827)
23. Demyttenaere K, Jaspers L (2008). Review: bupropion and SSRI-induced side effects. Journal of Psychopharmacology 22, 792-804.
24. Deng F, Price MG, Davis CF, Mori M, Burgess DL (2006). Stargazin and other transmembrane AMPA receptor regulating proteins interact with synaptic scaffolding protein MAGI-2 in brain. Journal of Neuroscience 26, 7875-7884. (Pubitemid 44315157)
25. Franchini L, Serretti A, Gasperini M, Smeraldi E (1998). Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. Journal of Psychiatric Research 32, 255-259. (Pubitemid 28410114)
26. Frost J, Sandvik P, Spigset O (2010). Sexual dysfunction induced by antidepressants [in Norwegian]. Tidsskrift for den Norske laegeforening 130, 1930-1931.
27. Garriock HA, Kraft JB, Shyn SI, Peters EJ, Yokoyama JS, Jenkins GD, Reinalda MS, Slager SL, McGrath PJ, Hamilton SP (2010). A genomewide association study of citalopram response in major depressive disorder. Biological Psychiatry 67, 133-138.
28. Goldstein H (1995). Multilevel Statistical Models. Arnold: London.
29. Harvey KV, Balon R (1995). Augmentation with buspirone: a review. Annals of Clinical Psychiatry 7, 143-147.
30. International HapMap Consortium (2005). A haplotype map of the human genome. Nature 437, 1299-1320.
31. Kato M, Serretti A (2010). Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Molecular Psychiatry 15, 473-500.
32. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, Brockmoller J (2004). Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Molecular Psychiatry 9, 442-473. (Pubitemid 38903502)
33. Lavedan C, Licamele L, Volpi S, Hamilton J, Heaton C, Mack K, Lannan R, Thompson A, Wolfgang CD, Polymeropoulos MH (2009). Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Molecular Psychiatry 14, 804-819.
34. Lei SF, Yang TL, Tan LJ, Chen XD, Guo Y, Guo YF, Zhang L, Liu XG, Yan H, Pan F, Zhang ZX, Peng YM, Zhou Q, He LN, Zhu XZ, Cheng J, Liu YZ, Papasian CJ, Deng HW (2009). Genome-wide association scan for stature in Chinese: evidence for ethnic specific loci. Human Genetics 125, 1-9.
35. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R (2008). SLCO1B1 variants and statin-induced myopathy-a genomewide study. New England Journal of Medicine 359, 789-799.
36. Liu C, Batliwalla F, Li W, Lee A, Roubenoff R, Beckman E, Khalili H, Damle A, Kern M, Furie R, Dupuis J, Plenge RM, Coenen MJ, Behrens TW, Carulli JP, Gregersen PK (2008a). Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Molecular Medicine 14, 575-581.
37. Liu Y, Boukhelifa M, Tribble E, Morin-Kensicki E, Uetrecht A, Bear JE, Bankaitis VA (2008b). The Sac1 phosphoinositide phosphatase regulates Golgi membrane morphology and mitotic spindle organization in mammals. Molecular Biology of the Cell 19, 3080-3096.
38. Liu YZ, Guo YF, Wang L, Tan LJ, Liu XG, Pei YF, Yan H, Xiong DH, Deng FY, Yu N, Zhang YP, Zhang L, Lei SF, Chen XD, Liu HB, Zhu XZ, Levy S, Papasian CJ, Drees BM, Hamilton JJ, Recker RR, Deng HW (2009). Genome-wide association analyses identify SPOCK as a key novel gene underlying age at menarche. PLoS Genetics 5, e1000420.
39. Loehlin JC (2004). Latent Variable Models: An Introduction to Factor, Path, and Structural Equation Analysis. Lawrence Erlbaum Associates: Mahwah, NJ.
40. Maddox JC, Levi M, Thompson C (1994). The compliance with antidepressants in general practice. Journal of Psychopharmacology 8, 48-53. (Pubitemid 24092317)
41. Malhotra AK, Murphy Jr. GM, Kennedy JL (2004). Pharmacogenetics of psychotropic drug response. American Journal of Psychiatry 161, 780-796. (Pubitemid 38625331)
42. McClay JL, Adkins DE, Aberg K, Bukszar J, Khachane AN, Keefe RS, Perkins DO, McEvoy JP, Stroup TS, Vann RE, Beardsley PM, Lieberman JA, Sullivan PF, van den Oord EJ (2011a). Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. Neuropsychopharmacology 36, 616-626.
43. McClay JL, Adkins DE, Aberg K, Stroup S, Perkins DO, Vladimirov VI, Lieberman JA, Sullivan PF, van den Oord EJ (2011b). Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Molecular Psychiatry 16, 76-85.
44. Mitchell AJ (2006). High medication discontinuation rates in psychiatry: how often is it understandable ? Journal of Clinical Psychopharmacology 26, 109-112. (Pubitemid 43740332)
45. Modell JG, May RS, Katholi CR (2000). Effect of bupropion-SR on orgasmic dysfunction in nondepressed subjects: a pilot study. Journal of Sex and Marital Therapy 26, 231-240. (Pubitemid 30439825)
46. Morag A, Pasmanik-Chor M, Oron-Karni V, Rehavi M, Stingl JC, Gurwitz D (2011). Genome-wide expression profiling of human lymphoblastoid cell lines identifies CHL1 as a putative SSRI antidepressant response biomarker. Pharmacogenomics 12, 171-184.
47. Muthén LK, Muthén BO (1998-2010). MPlus User's Guide. Muthe?n & Muthe?n: Los Angeles, CA.
48. Nunnally JC, Bernstein IH (1994). Psychometric Theory. McGraw-Hill: New York.
49. Oreilly RL, Bogue L, Singh SM (1994). Pharmacogentic response to antidepressants in a multicase family with affective disorder. Biological Psychiatry 36, 467-471. (Pubitemid 24308558)
50. Papakostas GI, Fava M (2009). Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. European Neuropsychopharmacology 19, 34-40.
51. Pare CMB, Mack JW (1971). Differentiation of two genetically specific types of depression by response to antidepressant drugs. Journal of Medical Genetics 8, 306-309.
52. Pinheiro JC, Bates DM (2000). Mixed-Effects Models in S and S-Plus. Springer: New York, NY.
53. Pollack MH, Reiter S, Hammerness P (1992). Genitourinary and sexual adverse effects of psychotropic medication. International Journal of Psychiatry in Medicine 22, 305-327. (Pubitemid 23084018)
54. Porcelli S, Drago A, Fabbri C, Gibiino S, Calati R, Serretti A (2011). Pharmacogenetics of antidepressant response. Journal of Psychiatry and Neuroscience 36, 87-113.
55. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, De Bakker PI, Daly MJ, Sham PC (2007). PLINK: a tool set for whole-genome association and population-based linkage analyses. American Journal of Human Genetics 81, 559-575. (Pubitemid 47330214)
56. Regier DA, Rae DS, Narrow WE, Kaelber CT, Schatzberg AF (1998). Prevalence of anxiety disorders and their comorbidity with mood and addictive disorders. British Journal of Psychiatry (Suppl.) 34, 24-28. (Pubitemid 28312194)
57. Rohde HM, Cheong FY, Konrad G, Paiha K, Mayinger P, Boehmelt G (2003). The human phosphatidylinositol phosphatase SAC1 interacts with the coatomer I complex. Journal of Biological Chemistry 278, 52689-52699. (Pubitemid 38035866)
58. Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, Thase ME, Nierenberg AA, Quitkin FM, Kashner TM, Kupfer DJ, Rosenbaum JF, Alpert J, Stewart JW, McGrath PJ, Biggs MM, Shores-Wilson K, Lebowitz BD, Ritz L, Niederehe G (2004). Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Controlled Clinical Trials 25, 119-142. (Pubitemid 38230109)
59. Safarinejad MR (2010). The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study. British Journal of Urology International 106, 840-847.
60. Sakurai K, Migita O, Toru M, Arinami T (2002). An association between a missense polymorphism in the close homologue of L1 (CHL1, CALL) gene and schizophrenia. Molecular Psychiatry 7, 412-415. (Pubitemid 34499363)
61. Searle SR, Casella G, McCulloch CE (1992). Variance Components. Wiley: New York.
62. Segraves RT (1989). Effects of psychotropic drugs on human erection and ejaculation. Archives of General Psychiatry 46, 275-284. (Pubitemid 19078265)
63. Serretti A, Chiesa A (2009). Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. Journal of Clinical Psychopharmacology 29, 259-266.
64. Souery D, Oswald P, Massat I, Bailer U, Bollen J, Demyttenaere K, Kasper S, Lecrubier Y, Montgomery S, Serretti A, Zohar J, Mendlewicz J (2007). Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. Journal of Clinical Psychiatry 68, 1062-1670.
65. Storey J (2003). The positive false discovery rate: a Bayesian interpretation and the q-value. Annals of Statistics 31, 2013-2035. (Pubitemid 38293903)
66. Storey JD, Tibshirani R (2003). Statistical significance for genomewide studies. Proceedings of the National Academy of Sciences USA 100, 9440-9445. (Pubitemid 37033947)
67. Uhl GR, Liu QR, Drgon T, Johnson C, Walther D, Rose JE, David SP, Niaura R, Lerman C (2008). Molecular genetics of successful smoking cessation: convergent genome-wide association study results. Archives of General Psychiatry 65, 683-693. (Pubitemid 351787239)
68. Van den Oord EJ, Adkins DE, McClay J, Lieberman J, Sullivan PF (2009). A systematic method for estimating individual responses to treatment with antipsychotics in CATIE. Schizophrenia Research 107, 13-21.
69. Wisniewski SR, Rush AJ, Balasubramani GK, Trivedi MH, Nierenberg AA (2006). Self-rated global measure of the frequency, intensity, and burden of side effects. Journal of Psychiatric Practice 12, 71-79. (Pubitemid 44284089)
70. Wright GJ, Leslie JD, Ariza-McNaughton L, Lewis J (2004). Delta proteins and MAGI proteins: an interaction of Notch ligands with intracellular scaffolding molecules and its significance for zebrafish development. Development 131, 5659-5669. (Pubitemid 39625209)
71. Zobel A, Maier W (2010). Pharmacogenetics of antidepressive treatment. European Archives of Psychiatry and Clinical Neuroscience 260, 407-417.